Global Dyslipidemia Market, By Drug Class (Statin Drugs, Non-Statin Lipid–Lowering Drugs), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Store, Online Pharmacies) – Industry Trends and Forecast to 2030.
Dyslipidemia Market Analysis and Size
The rapid increase in high- and low-density lipoprotein levels acts as one of the major factors driving the growth of the dyslipidemia market. Likewise, the rise in the global geriatric population, which is more prone to cardiovascular disorders, and the presence of a large geriatric population base are also predictable to enhance the dyslipidemia market growth. Furthermore, the imminent biotechnological products such as monoclonal antibodies for treating lipid disorders, diseases inducing lifestyle habits such as tobacco smoking and chewing, high salt intake, high cholesterol intake, and weight gain are also projected to drive the market growth rate. Also, the increase in the prevalence of lifestyle diseases and the rise in acceptance of telemental health are expected to influence the global dyslipidemia market growth in the forecast period.
Data Bridge Market Research analyses that the global dyslipidemia market, which was USD 15.05 billion in 2022, and would rocket up to USD 22.09 billion by 2030, and is expected to undergo a CAGR of 5.00% during the forecast period. This indicates that the market value. "Hospital Pharmacies" dominates the distribution channel segment of the global dyslipidemia market owing to the growing demand for drugs. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Dyslipidemia Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Drug Class (Statin Drugs, Non-Statin Lipid–Lowering Drugs), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Store, Online Pharmacies)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
AstraZeneca (U.K.), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Sanofi (France), Alnylam Pharmaceuticals, Inc. (U.S.), AMARIN CORPORATION (Ireland), Amgen Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Mylan N.V. (U.S.), Catabasis Pharmaceuticals (U.S.), Cipla Inc. (India), DAEWOONG BIO (South Korea), DAIICHI SANKYO COMPANY, LIMITED (Japan), Eli Lilly and Company (U.S.), ESPERION Therapeutics, Inc. (U.S.), GlaxoSmithKline plc (U.K.), JW Pharmaceutical (South Korea), Lupin Pharmaceuticals, Inc. (India), Teva Pharmaceutical Industries Ltd (Israel), Novartis AG (Switzerland), and Bayer AG (Germany) among others
|
|
Market Opportunities
|
|
Market Definition
Dyslipidemia is a condition that is characterized by abnormal levels of lipids in the blood. Lipids are fats and oils essential for the body to function properly. There are several different types of lipids, including triglycerides, cholesterol, and phospholipids. Dyslipidemia can cause various health problems, including heart disease and stroke. There are several drugs available to treat dyslipidemia. These drugs include statins, which reduce the amount of cholesterol in the blood; fibrates, which lower triglyceride levels; and ezetimibe, which reduces the amount of cholesterol absorbed from food.
Global Dyslipidemia Market Dynamics
Drivers
- Rising incidences of people with triglyceride and cholesterol abnormalities
The cases of chronic heart diseases are growing exponentially and will likely drive the worldwide dyslipidemia market. The increase in the prevalence of chronic diseases such as immune disorders and cardiovascular diseases drives the market. Rising cardiovascular issues are projected to promote the global dyslipidemia market size in the upcoming years.
Dyslipidemia is one of the most dangerous cardiovascular disorders, per several government and corporate groups involved in the cholesterol medicine business. The Centers for Disease Control and Prevention (CDC) estimated that 95 million individuals (55% of the population) in the U.S. had a total cholesterol level higher than 200 mg/dL. In addition, approximately 29 million adults in the U.S. have a total level of cholesterol over 240 mg/dL. As a result, the global dyslipidemia drugs market will likely be driven by a huge population suffering from the disease during the forecast period.
- Rising geriatric population
The expanding senior population worldwide is predicted to favor the demand for dyslipidemia as this population is more prone to heart diseases. The number of persons above 65 is projected to double in the coming years. Old-age people are prone to various chronic diseases such as cardiovascular diseases, endovascular diseases, orthopedic disorders, and dental disorders, which can foster the demand for dyslipidemia across the globe.
According to the United Nations, there were around 382 million people aged 60 years or above across the globe in 2017, which is expected to be 2.1 billion by 2050.
- Advancement of therapies for the treatment
Advancement of therapies for the treatment are the expected factors that will increase the growth of the dyslipidemia market. Moreover, it is anticipated that the market for dyslipidemia will exhibit lucrative growth, as several market participants are focusing on R&D to develop novel treatments. Participants are actively engaged in extensive research and development to develop novel drugs to treat various heart disorders and gain a larger market share. As the number of individuals with diseases continues to rise at an alarming rate, there is a growing demand for treatment.
Opportunity
- Increase in government funds and support
An increase in government funds and support for target research activities and rising product innovations and development worldwide will extend profitable opportunities for the market players from 2023 to 2030. Moreover, the development of novel pharmaceuticals for the treatment of dyslipidemia as well as collaborations & collaborative contracts with other firms, are among the top priorities of key competitors in the global dyslipidemia drugs market. These leading players' approaches are anticipated to expedite future market expansion for dyslipidemia.
Restraint/Challenge
- High capital requirement for R&D
High capital requirements for biotechnology-based R&D drug development and patent expiry from many companies are expected to act as major restraints towards the growth of the dyslipidemia market. Moreover, poor patient compliance in some countries can challenge the growth of the target market in the forecast period of 2023-2030.
This global dyslipidemia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global dyslipidemia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In August 2022, Esperion indicated that bempedoic acid (NEXLETOL) was recommended as an important oral non-statin therapy for LDL-cholesterol (LDL-C) lowering in the management of atherosclerotic cardiovascular disease (ASCVD) by the American College of Cardiology (ACC) task force on expert consensus decision pathways (ECDP)
- In May 2022, Zydus Lifesciences launched its Bempedoic acid drug in India under the Bemdac brand for the treatment of uncontrolled levels of bad cholesterol
- In November 2021, Pfizer announced topline results from the Phase 2b study of vupanorsen (PF-07285557), an investigational antisense therapy being developed for potential indications in cardiovascular (CV) risk reduction and severe hypertriglyceridemia (SHTG). The study showed that vupanorsen achieved a statistically significant lowering of non-HDL-C, triglycerides, and other lipoproteins related to cardiovascular disease
Global Dyslipidemia Market Scope
The global dyslipidemia market is segmented on the basis of drug class and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Statin Drugs
- High-Intensity
- Moderate-Intensity
- Low-Intensity
- Non-Statin Lipid–Lowering Drugs
- Bile Acid Sequestrants
- Cholesterol Absorption Inhibitor
- Fibrates
- Nicotinic Acid
- Pcsk9 Monoclonal Antibodies
- Omega-3 Fatty Acids
- Combination Products
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Drug Store
- Online Pharmacies
Global Dyslipidemia Market Regional Analysis/Insights
The global dyslipidemia market is analysed and market size insights and trends are provided by country, drug class and distribution channel as referenced above.
The countries covered in the global dyslipidemia market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the global dyslipidemia market due to the rapid biotechnological developments and development in healthcare infrastructure within the region.
Asia-Pacific is expected to grow at the highest growth rate during the forecast period of 2023 to 2030 due to the increase in incidence rates of diabetes and obesity and unhealthy lifestyle conditions such as stress and high cholesterol intake in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The global dyslipidemia market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for dyslipidemia market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the dyslipidemia market. The data is available for historic period 2010-2021.
Competitive Landscape and Global Dyslipidemia Market Share Analysis
The global dyslipidemia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the global dyslipidemia market are:
- AstraZeneca (U.K.)
- Merck & Co., Inc. (U.S.)
- Pfizer Inc.(U.S.)
- Sanofi (France)
- Alnylam Pharmaceuticals, Inc. (U.S.)
- AMARIN CORPORATION (Ireland)
- Amgen Inc.(U.S.)
- Bristol-Myers Squibb Company (U.S.)
- Mylan N.V. (U.S.)
- Catabasis Pharmaceuticals (U.S.)
- Cipla Inc (India)
- DAEWOONG BIO (South Korea)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)
- Eli Lilly and Company (U.S.)
- ESPERION Therapeutics, Inc.(U.S.)
- GlaxoSmithKline plc (U.K.)
- JW Pharmaceutical (South Korea)
- Lupin Pharmaceuticals, Inc. (India)
- Teva Pharmaceutical Industries Ltd (Israel)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
SKU-